Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.47 |
| ▸ | BACE2 | Q9Y5Z0 | 6/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | PPIA | P62937 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15366841 | 0.93 | BACE1 (0.46) | BACE1BACE2GRM5RAB9ANPC1 | |
| SCHEMBL14733557 | 0.88 | BACE1 (0.43) | BACE1BACE2GRM5TP53MDM2 | |
| SCHEMBL19725798 | 0.87 | BACE1 (0.49) | BACE1BACE2GRM5FFAR4RAB9A | |
| SCHEMBL15768842 | 0.83 | BACE1 (0.38) | BACE1BACE2RAB9ANPC1LMNA | |
| SCHEMBL15768807 | 0.80 | BACE1 (0.36) | BACE1BACE2LMNAALDH1A1 | |
| SCHEMBL15798977 | 0.80 | BACE1 (0.36) | BACE1BACE2LMNAALDH1A1 | |
| SCHEMBL15366789 | 0.80 | BACE1 (0.45) | BACE1BACE2RAB9ANPC1LMNA | |
| SCHEMBL14733555 | 0.80 | BACE1 (0.35) | BACE1BACE2FFAR4TP53MDM2 | |
| SCHEMBL14716789 | 0.79 | BACE1 (0.39) | BACE1BACE2GRM5FFAR4LMNA | |
| SCHEMBL15938986 | 0.79 | BACE1 (0.43) | BACE1BACE2RAB9ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550795-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2017-01-24 | — | — | US | disclosed |
| EP-2751116-B1 | HEXAHYDROPYRANO [3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20150087637-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-8933221-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20130053373-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | BRODNEY MICHAEL AARON (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053373-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | DPYD, TPMT, QDPR | BACE1 3093/4885BACE2 2953/4885GRM5 1554/4885 |
| US-20150087637-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | DPYD, TPMT, QDPR | BACE1 3093/4885BACE2 2953/4885GRM5 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.